PRESS RELEASES

Oct 13, 2014
The Next Generation of DNA Vaccines Is Poised to Transform the Healthcare Landscape
Oct 01, 2014
ITI Filing an IND for a Phase II Study
Sep 17, 2014
ITI Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy
Aug 21, 2014
Relief for Allergy Sufferers Finally in Sight – Phase IC
Jun 29, 2014
Immunomic Therapeutics Engages Newport Coast Securities, Inc.
Jun 28, 2014
String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline
Jun 17, 2014
ITI Announces Significant Strides in Peanut Allergy Vaccine Development
May 19, 2014
ITI CEO Appointed to Panel at Prestigious Future in Review Conference
Apr 03, 2014
ITI Announces Data Analysis of Phase IB Study to Treat Japanese Red Cedar Allergy
Nov 07, 2013
ITI's Process Development Laboratory at Hershey is Now Operational
Oct 22, 2013
ITI's Medical Monitor, Dr. Lawrence Weiner, to Present at the 2013 ACAAI Annual Scientific Meeting
Jul 12, 2013
ITI Closes $3 Million Debt Pre-Series B Round
Jun 19, 2013
Myriad Supreme Court Case Has Promising Outcome for Immunomic Therapeutics
Apr 24, 2013
ITI Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy
Apr 10, 2013
ITI Announces Bernard C. Rudnick’s Nomination to the Board of Directors
Mar 25, 2013
ITI Has Generated More Than $6.5 Million in Funding To Date
Feb 22, 2013
ITI Receives Notice of Issuance for Chimeric Vaccines Patent
Jan 24, 2013
ITI Completes Patient Enrollment into Phase I protocol
Nov 5, 2012
Entering First Patients into Phase I protocol
Oct 25, 2012
New Process Development Laboratory at HCAR
Aug 2, 2012
Immunomic Therapeutics Receives Notice of Patent Allowance For Chimeric Vaccines, a Core Component of LAMP-Vax™ Vaccines
May 24, 2012
Immunomic Therapeutics’ CEO, Dr. William G. Hearl, to Present at the 2012 BIO International Convention in June
May 2, 2012
Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRCLAMP- Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
May 2, 2012
Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRCLAMP- Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy in JAPANESE
Apr 24, 2013
Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy
March 26, 2012
Filing of IND for JRC-LAMP-vax
Jan 9, 2012
Iti Secures Phase I Funding For Japanese Red Cedar Lamp Vaccine
Jan 1, 2012
LAMP Technology Promises Next Generation Vaccines to Improving Human Health
Apr 1, 2011
Immunomic Therapeutics Shareholders Elect Board, Barry McDonald as Chair.
NEWSLETTERS

Hay Fever from Texas to Japan
ITI Newsletter Feb 2014
ITI Newsletter Sep 2013
ITI Newsletter Jun 2013
ITI Newsletter Mar 2013
ITI Newsletter Feb 2013

COMPANY
TECHNOLOGY
CLINICAL
MEDIA
Immunomic Therapeutics, Inc.
Headquarters: 1214 Research Blvd, Suite 2016, Hershey, PA 17036
Phone: 717-327-1919
Lab: 15010 Broschart Rd. Ste. 250, Rockville, MD 20850
Phone: 866-515-9484

© 2007-2013 Immunomic Therapeutics, Inc.
All rights reserved
by: Design Media Land, LLC